• Profile
Close

Cardiorenal status using amino-terminal pro–brain natriuretic peptide and cystatin C on cardiac resynchronization therapy outcomes: From the BIOCRT Study

Heart Rhythm Feb 01, 2019

Truong QA, et al. - In this study with 92 patients (age 66 ± 13 years; 80% male; left ventricular ejection fraction 26% ± 7%), researchers investigated how cardiac resynchronization therapy (CRT) outcomes were influenced by cardiorenal status using a dual-marker strategy with amino-terminal pro–brain natriuretic peptide (NT-proBNP) and cystatin C. At CRT implantation and at 1 month, they assessed NT-proBNP and cystatin C levels; categories of CRT patients were defined at 1 month. They assessed 6-month clinical and echocardiographic CRT response and 2 -year major adverse cardiovascular events. Findings revealed that high-risk CRT patients could be detected by assessing cardiorenal status by NT-proBNP and cystatin C, and worse prognosis was observed among those with elevated concentrations of both.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay